Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection

Qianfoshan Hospital

Status: Enrolling

Conditions: Cardiotoxicity; Adverse Reaction; Evaluation Study

Treatments: Drug: Sodium arsenite chloride injection

Study type: Observational

Funder types: Other

Identifiers

NCT06060132

YSS001

Details and patient eligibility

About

To study the current status of cardiotoxicity of arsenious acid by analyzing the literature, monitoring data, and real-world applications, and to discuss risk factors and preventive and control measures.

Full description

Through the project study, the risk rate of cardiotoxicity caused by arsenious acid will be verified and evaluated, and a typical case analysis will be conducted to assess the risk and benefit ratio of clinical use of arsenious acid injection and to formulate preventive measures, so as to guide the holder of the marketing authorization to carry out in-depth safety studies and to ensure the public's safe use of the drug.

Enrollment: 400 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• the period of consultation (for inpatients, according to the time of admission) is from January 1, 2012 to December 31, 2022
• the patient used arsenite sodium chloride injection

Exclusion criteria

• Patients with incomplete clinical information